The express and biology value of p-MET in renal cell carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022588

Enrollment

Unknown

Registered

2019-04-17

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

Renal cell carcinoma with high expression of phosphorylation MET:No

Paracancerous tissue with low expression of phosphorylated MET:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnosed as kidney tumor patient by Hematuria, auxiliary examination 2.Collecting Blood, urine and tumor tissue with informed consent

Exclusion criteria

Exclusion criteria: Renal hamartoma,hemangioma et al

Design outcomes

Primary

Measure	Time frame
phosphorylation -MET;	—

Countries

China

Contacts

Public ContactLibo Xie

Affiliated Hospital of Southwest Medical Univeristy

peterxielibo@163.com+86 18208344963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026